Randomized trial evaluates progression-free survival by homologous recombination and BRCA1/2 status in ovarian cancer with IC ≥5%, highlighting biomarker-driven immunotherapy response.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Landen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: